此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

马立达巴特卡夫拉鲁肽对心脏电活动的影响

2026年9月18日 更新者:Amgen

一项1期、随机、双盲、安慰剂和阳性对照、平行分组研究,采用嵌套交叉比较设计,评估Maridebart Cafraglutide对超重或肥胖参与者QT/QTc间期的影响

The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.

研究概览

研究类型

介入性

注册 (实际的)

81

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Florida
      • Daytona Beach、Florida、美国、32117-5116
        • Fortrea Clinical Research Unit - Daytona Beach
    • Texas
      • Dallas、Texas、美国、75247-4968
        • Fortrea Clinical Research Unit - Dallas

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria

To take part in the trial, participants must meet all of the following:

  1. Provide signed and dated informed consent before any trial procedures.

  2. Be able to understand the trial requirements, sign the consent form, and follow trial restrictions.

  3. Male or female, of any race, between 18 and 60 years old (inclusive).

    • Females must not be pregnant or breastfeeding.
    • Males and females who could become pregnant must agree to use effective birth control as specified in the protocol.
  4. Body mass index (BMI) between 25.0 and 35.0 kg/m^2 (inclusive).

  5. No major changes in diet or lifestyle in the past 3 months, based on self-report.

  6. Stable body weight (less than 5 kg change) in the past 3 months, based on self-report.

  7. Blood potassium, calcium, and magnesium within the normal range at screening and at check-in for the first treatment period.

  8. Participants with controlled high blood pressure, cholesterol problems, or hypothyroidism on stable treatment for at least 3 months may be included (except for medicines known to affect heart rhythm or interact with moxifloxacin). Other mild, stable health conditions may be allowed with approval from the investigator and medical monitor.

Exclusion Criteria

Participants will not be able to take part if they meet any of the following:

Medical Conditions

  1. Any significant medical condition or abnormal test result that, in the opinion of the investigator, could pose a risk or interfere with trial participation.

  2. History of diabetes (any type, except past gestational diabetes), or Haemoglobin A1c (HbA1c) ≥ 6.5% at screening.

  3. History of pancreatitis within the past year, or high blood tests suggesting pancreatic problems (lipase/amylase > 2× normal, or fasting triglycerides > 500 mg/dL).

  4. Liver enzymes (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) more than 2× the upper limit of normal.

  5. Kidney function (estimated glomerular filtration rate [eGFR]) < 70 mL/min/1.73 m^2.

  6. Cancer within the last 5 years (except treated nonmelanoma skin cancers or in situ cervical/breast lesions).

  7. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.

  8. Uncontrolled thyroid disease (abnormal thyroid-stimulating hormone [TSH] outside 0.4-6.0 mIU/L).

  9. Contraindications to moxifloxacin, including history of tendon disorders with quinolone use.

  10. History of gastrointestinal surgery or disease that may affect absorption of oral drugs (other than uncomplicated appendectomy or hernia repair).

  11. Inability to swallow pills.

  12. History of significant esophageal, stomach, or bowel disorders (eg, ulcers, bleeding, Crohn's disease, ulcerative colitis, irritable bowel syndrome, gastroparesis).

  13. Current or recent suicidal thoughts (per Columbia Suicide Severity Rating Scale [C-SSRS]).

  14. Lifetime history of suicide attempt or behavior.

  15. Major depressive disorder within the past 2 years.

  16. History of other serious psychiatric disorders (eg, schizophrenia, bipolar disorder).

  17. High depression score (patient health questionnaire-9 [PHQ-9] ≥ 15).

  18. History or current signs of heart disease (eg, heart attack, congenital defects, valve disease, angina, bypass or stent).

  19. History of ischemic optic neuropathy (eye damage from poor blood flow).

  20. Diagnosis of sleep apnea. Diagnostic Tests

  21. Positive test for human immunodeficiency virus (HIV).

  22. Positive test for hepatitis B or C (exceptions apply for prior vaccination or resolved infection).

  23. Abnormal vital signs: average blood pressure > 140/90 mmHg or < 90/50 mmHg, or heart rate > 110 or < 40 bpm.

  24. Abnormal ECG findings at screening or check-in, including:

    • QTcF > 450 ms (males) or > 470 ms (females).
    • QRS > 120 ms, PR > 220 ms, AV block (2nd or 3rd degree).
    • Findings that make QTc measurement unreliable.
    • Risk factors for dangerous arrhythmias (eg, heart failure, low potassium, long QT syndrome).
    • Clinically significant arrhythmias. Medications
  25. Use of drugs that affect absorption, metabolism, or elimination within 30 days of dosing.

  26. Use of drugs known to prolong QT/QTc within 30 days of dosing.

  27. Use of prescription drugs (other than hormone replacement or contraception) within 14 days of dosing.

  28. Use of long-acting/slow-release medicines still active within 14 days of dosing.

  29. Use of non-prescription products (vitamins, supplements, herbal products) within 7 days of dosing.

  30. Use of glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) receptor agonists/antagonists within 3 months of check-in.

    Other Clinical Trial Experience

  31. Participation in another investigational drug trial within 30 days or 5 drug half-lives (whichever is longer).

  32. Previous exposure to maridebart cafraglutide in this or another trial. Lifestyle

  33. Alcohol use > 21 units/week (men) or > 14 units/week (women).

  34. Alcohol use within 48 hours before check-in.

  35. Positive drug screen or alcohol test at screening or check-in.

  36. History of alcohol or drug abuse within 1 year.

  37. Use of tobacco/nicotine products within 3 months, or positive cotinine test.

  38. Use of caffeine within 48 hours of screening or check-in.

  39. Consumption of grapefruit, Seville orange, or related products within 7 days of check-in.

  40. Consumption of poppy seed-containing foods within 7 days of check-in. Other

  41. Receipt of blood products within 2 months before check-in.

  42. Blood donation within 3 months; plasma donation within 2 weeks; platelet donation within 6 weeks.

  43. Poor veins for blood draws.

  44. Any other reason, in the opinion of the investigator, the participant should not take part.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Group 1

In treatment period 1, participants will receive placebo for moxifloxacin.

In treatment period 2, participants will receive maridebart cafraglutide.

In treatment period 3, participants will receive placebo for moxifloxacin.

Participants will receive maridebart cafraglutide SC.

其他名称:
  • AMG 133

Participants will receive placebo for moxifloxacin orally.

实验性的:Group 2A

In treatment period 1, participants will receive moxifloxacin.

In treatment period 2, participants will receive placebo for maridebart cafraglutide.

In treatment period 3, participants will receive placebo for moxifloxacin.

Participants will receive placebo for moxifloxacin orally.

Participants will receive moxifloxacin orally.

Participants will receive placebo for maridebart cafraglutide SC.

实验性的:Group 2B

In treatment period 1, participants will receive placebo for moxifloxacin.

In treatment period 2, participants will receive placebo for maridebart cafraglutide.

In treatment period 3, participants will receive moxifloxacin.

Participants will receive placebo for moxifloxacin orally.

Participants will receive moxifloxacin orally.

Participants will receive placebo for maridebart cafraglutide SC.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from Baseline in QTcF for Maridebart Cafraglutide
大体时间:Up to Day 171

Change from baseline in QTcF for maridebart cafraglutide will be the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QTcF after maridebart cafraglutide dosing.

Up to Day 171

次要结果测量

结果测量
措施说明
大体时间
马利德巴特卡夫拉鲁肽给药间隔内浓度-时间曲线下面积(AUCtau)
大体时间:至第171天
至第171天
马拉德巴特卡夫拉鲁肽的最大观察浓度 (Cmax)
大体时间:至第171天
至第171天
QTcF的分类离群值
大体时间:至第171天
至第171天
HR分类异常值
大体时间:至第171天
至第171天
PR分类异常值
大体时间:截至第171天
截至第171天
QRS分类离群值
大体时间:截至第171天
截至第171天
出现治疗引起心电图(ECG)形态学改变的受试者人数
大体时间:截至第171天
截至第171天
出现治疗突发不良事件和严重不良事件的受试者人数
大体时间:截至第232天
截至第232天
产生抗马利德巴特卡非格鲁肽抗体的受试者人数
大体时间:截至第232天
截至第232天
Change from Baseline in Heart Rate
大体时间:Up to Day 171

Change from baseline in heart rate will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in HR for the by-time point analysis.

Up to Day 171
Change from Baseline in PR Interval
大体时间:Up to Day 171

Change from baseline in PR Interval will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in PR for the by-time point analysis.

Up to Day 171
Change from Baseline in QRS Duration
大体时间:Up to Day 171

Change from baseline in QRS Duration will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QRS for the by-time point analysis.

Up to Day 171
Change from Baseline in QTcF for Moxifloxacin
大体时间:Up to Day 171

Change from baseline in QTcF for moxifloxacin will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QTcF after moxifloxacin dosing for both the assay sensitivity and by-time point analysis.

Up to Day 171

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:MD、Amgen

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年10月22日

初级完成 (实际的)

2026年8月27日

研究完成 (实际的)

2026年8月27日

研究注册日期

首次提交

2025年11月13日

首先提交符合 QC 标准的

2025年11月13日

首次发布 (实际的)

2025年11月14日

研究记录更新

最后更新发布 (实际的)

2026年9月22日

上次提交的符合 QC 标准的更新

2026年9月18日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

IPD 共享时间框架

Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

IPD 共享访问标准

Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅